Next Article in Journal
Exploring Kinase Inhibition Properties of 9H-pyrimido[5,4-b]- and [4,5-b]indol-4-amine Derivatives
Next Article in Special Issue
Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents
Previous Article in Journal
Vasorelaxant Effects Induced by Red Wine and Pomace Extracts of Magliocco Dolce cv.
Previous Article in Special Issue
Drug Conjugates for Targeting Eph Receptors in Glioblastoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 13
Issue 5
10.3390/ph13050088
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Antibody Targeting of Eph Receptors in Cancer

by
Peter W. Janes
*,
Mary E. Vail
,
Hui K. Gan
and
Andrew M. Scott
Olivia Newton-John Cancer Institute and La Trobe University School of Cancer Medicine, Victoria 3084, Australia
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(5), 88; https://doi.org/10.3390/ph13050088
Submission received: 8 April 2020 / Revised: 29 April 2020 / Accepted: 4 May 2020 / Published: 8 May 2020
(This article belongs to the Special Issue Targeting the Eph–ephrin System)
Browse Figure
Versions Notes

Abstract

The Eph subfamily of receptor tyrosine kinases mediate cell-cell communication controlling cell and tissue patterning during development. While generally less active in adult tissues, they often re-emerge in cancers, particularly on undifferentiated or progenitor cells in tumors and the tumor microenvironment, associated with tumor initiation, angiogenesis and metastasis. Eph receptors are thus attractive therapeutic targets, and monoclonal antibodies have been commonly developed and tested for anti-cancer activity in preclinical models, and in some cases in the clinic. This review summarizes 20 years of research on various antibody-based approaches to target Eph receptors in tumors and the tumor microenvironment, including their mode of action, tumor specificity, and efficacy in pre-clinical and clinical testing.
Keywords: Eph receptor; therapeutic antibodies; cancer Eph receptor; therapeutic antibodies; cancer

Share and Cite

MDPI and ACS Style

Janes, P.W.; Vail, M.E.; Gan, H.K.; Scott, A.M. Antibody Targeting of Eph Receptors in Cancer. Pharmaceuticals 2020, 13, 88. https://doi.org/10.3390/ph13050088

AMA Style

Janes PW, Vail ME, Gan HK, Scott AM. Antibody Targeting of Eph Receptors in Cancer. Pharmaceuticals. 2020; 13(5):88. https://doi.org/10.3390/ph13050088

Chicago/Turabian Style

Janes, Peter W., Mary E. Vail, Hui K. Gan, and Andrew M. Scott. 2020. "Antibody Targeting of Eph Receptors in Cancer" Pharmaceuticals 13, no. 5: 88. https://doi.org/10.3390/ph13050088

APA Style

Janes, P. W., Vail, M. E., Gan, H. K., & Scott, A. M. (2020). Antibody Targeting of Eph Receptors in Cancer. Pharmaceuticals, 13(5), 88. https://doi.org/10.3390/ph13050088

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop